New PBM Models Aim To Lower Out-Of-Pocket Costs

Start-up pharmacy benefit managers such as Capital Rx and Evio hope to shake up the traditional PBM service model with increased drug price transparency, aggregated real-world data and outcomes-based contracting. The big three PBMs which dominate the market represent a formidable challenge.

health care costs
• Source: Alamy

Better price transparency and high-tech analyses of pharmacy benefit manager (PBM)beneficiary data as methods for lowering drug costs are a common refrain among PBMs large and small; Optum, UnitedHealth Group’s $100bn pharmacy services business, for example, has been promoting the concept of analyzing patient data and claims information to lower drug costs for nearly a decade. However, shifts in benefit structures, from high-deductible health plans and co-insurance payments to narrow drug formularies and integrated drug and medical benefits, have led US consumers, who pay more out of pocket than anyone else (see Exhibit 1) to search for new ways to lower costs.

Coupon card platforms like GoodRx and Blink Health have made significant inroads with consumers, and a growing number of health...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Access

More from In Vivo

Deals Shaping The Industry, May 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Podcast: Flagship’s Vision To Predict And Prevent Illness, With Raj Panjabi

 
• By 

Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology

 

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.